JP2009513575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009513575A5 JP2009513575A5 JP2008534486A JP2008534486A JP2009513575A5 JP 2009513575 A5 JP2009513575 A5 JP 2009513575A5 JP 2008534486 A JP2008534486 A JP 2008534486A JP 2008534486 A JP2008534486 A JP 2008534486A JP 2009513575 A5 JP2009513575 A5 JP 2009513575A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- fluoro
- imidazol
- pyrimidin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 125000000623 heterocyclic group Chemical group 0.000 claims 38
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- -1 hydrogen radicals Chemical group 0.000 claims 30
- 125000005843 halogen group Chemical group 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000004429 atom Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 239000012458 free base Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- VGSQFKCYTNOWJM-UHFFFAOYSA-N (2,6-dimethylmorpholin-4-yl)-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1C(C)OC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 VGSQFKCYTNOWJM-UHFFFAOYSA-N 0.000 claims 1
- JUHQUEWVIIDBNH-UHFFFAOYSA-N (3,3-difluoroazetidin-1-yl)-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CC(F)(F)C1 JUHQUEWVIIDBNH-UHFFFAOYSA-N 0.000 claims 1
- UHDXDZQXNNJWDY-UHFFFAOYSA-N (3,3-difluoropyrrolidin-1-yl)-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(F)(F)C1 UHDXDZQXNNJWDY-UHFFFAOYSA-N 0.000 claims 1
- AUDGHHREDWBFOE-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1CN(CC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 AUDGHHREDWBFOE-UHFFFAOYSA-N 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- DNLNSPKWMVGBHG-UHFFFAOYSA-N 2-amino-N-[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]-N-(oxan-4-yl)benzamide hydrochloride Chemical compound Cl.NC1=C(C(=O)N(C2CCOCC2)C2=NC=C(C(=N2)C=2N(C(=NC2)C)C2CCOCC2)F)C=CC=C1 DNLNSPKWMVGBHG-UHFFFAOYSA-N 0.000 claims 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- ADLMNARJRRPSOT-UHFFFAOYSA-N 3-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]benzonitrile;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=CC(C#N)=C1 ADLMNARJRRPSOT-UHFFFAOYSA-N 0.000 claims 1
- QLNHZJLXRCTCMN-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-methylsulfonylphenyl)pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(N=1)=CC=NC=1NC1=CC=C(S(C)(=O)=O)C=C1 QLNHZJLXRCTCMN-UHFFFAOYSA-N 0.000 claims 1
- HYESJXMPFNNNAW-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-morpholin-4-ylsulfonylphenyl)pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCOCC1 HYESJXMPFNNNAW-UHFFFAOYSA-N 0.000 claims 1
- XHOMOFSUGNNYMU-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-pyrrolidin-1-ylsulfonylphenyl)pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCCC1 XHOMOFSUGNNYMU-UHFFFAOYSA-N 0.000 claims 1
- KJJXNFGGNQIJRQ-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[3-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=CC(NC=2N=C(C=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)=C1 KJJXNFGGNQIJRQ-UHFFFAOYSA-N 0.000 claims 1
- WDBIOFPEYDNNET-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 WDBIOFPEYDNNET-UHFFFAOYSA-N 0.000 claims 1
- BWNKOIBHTVEFEQ-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(4-propan-2-ylpiperazin-1-yl)sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CN(C(C)C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 BWNKOIBHTVEFEQ-UHFFFAOYSA-N 0.000 claims 1
- HDLRWDBVGGDOBV-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1CN1CCOCC1 HDLRWDBVGGDOBV-UHFFFAOYSA-N 0.000 claims 1
- CIUVREIHECGYBX-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n,n-dimethylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 CIUVREIHECGYBX-UHFFFAOYSA-N 0.000 claims 1
- BDXZIUJTKUIELX-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]benzonitrile;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(C#N)C=C1 BDXZIUJTKUIELX-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- BLFWGFFZXXRNOQ-UHFFFAOYSA-N 5-[5-fluoro-2-[4-(4-methylpiperazin-1-yl)sulfonylanilino]pyrimidin-4-yl]-1-(oxan-4-yl)imidazole-2-carbonitrile Chemical compound C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C#N)=NC=2)C2CCOCC2)=N1 BLFWGFFZXXRNOQ-UHFFFAOYSA-N 0.000 claims 1
- HOKUVVAWNADSQH-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(3-methylsulfonylphenyl)pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=CC(S(C)(=O)=O)=C1 HOKUVVAWNADSQH-UHFFFAOYSA-N 0.000 claims 1
- JHVNKPANIZNDOB-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-methylsulfonylphenyl)pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(S(C)(=O)=O)C=C1 JHVNKPANIZNDOB-UHFFFAOYSA-N 0.000 claims 1
- MCCNGBGRWZAASD-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-morpholin-4-ylsulfonylphenyl)pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCOCC1 MCCNGBGRWZAASD-UHFFFAOYSA-N 0.000 claims 1
- JFZIVITZPGBERZ-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-piperazin-1-ylsulfonylphenyl)pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCNCC1 JFZIVITZPGBERZ-UHFFFAOYSA-N 0.000 claims 1
- KVUCXDUGBPIVIY-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-propan-2-ylsulfonylphenyl)pyrimidin-2-amine Chemical compound C1=CC(S(=O)(=O)C(C)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 KVUCXDUGBPIVIY-UHFFFAOYSA-N 0.000 claims 1
- CUXVJGARBZCZCY-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-pyrrolidin-1-ylsulfonylphenyl)pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCCC1 CUXVJGARBZCZCY-UHFFFAOYSA-N 0.000 claims 1
- XWUFNANHAZTEFC-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[3-methylsulfonyl-4-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1S(C)(=O)=O)=CC=C1CN1CCOCC1 XWUFNANHAZTEFC-UHFFFAOYSA-N 0.000 claims 1
- BMCLFHVOOIZFNK-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(1-morpholin-4-ylethyl)phenyl]pyrimidin-2-amine Chemical compound C=1C=C(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)C=CC=1C(C)N1CCOCC1 BMCLFHVOOIZFNK-UHFFFAOYSA-N 0.000 claims 1
- UTFUIZWRDLATQF-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(2-morpholin-4-ylethyl)phenyl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1CCN1CCOCC1 UTFUIZWRDLATQF-UHFFFAOYSA-N 0.000 claims 1
- FMEORCWNFFMXER-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(4-methylpiperazin-1-yl)sulfonyl-3-(trifluoromethoxy)phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C(C(=C1)OC(F)(F)F)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 FMEORCWNFFMXER-UHFFFAOYSA-N 0.000 claims 1
- OTGRAAUTGFNVIC-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 OTGRAAUTGFNVIC-UHFFFAOYSA-N 0.000 claims 1
- PEYBMQWFUHAKRT-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1CN1CCOCC1 PEYBMQWFUHAKRT-UHFFFAOYSA-N 0.000 claims 1
- HPWNIPMSABCNAE-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(oxan-2-ylmethylsulfonyl)phenyl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1S(=O)(=O)CC1CCCCO1 HPWNIPMSABCNAE-UHFFFAOYSA-N 0.000 claims 1
- BCPCWRAHMRSSBP-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(C(F)(F)F)C=C1 BCPCWRAHMRSSBP-UHFFFAOYSA-N 0.000 claims 1
- ZCNYDSWSOIKGPQ-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(S(C)(=O)=O)C(C(F)(F)F)=C1 ZCNYDSWSOIKGPQ-UHFFFAOYSA-N 0.000 claims 1
- IOLWECNTCVXLQV-UHFFFAOYSA-N 5-fluoro-4-[3-methyl-2-(trifluoromethyl)imidazol-4-yl]-n-[4-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.N1=C(C(F)(F)F)N(C)C(C=2C(=CN=C(NC=3C=CC(CN4CCOCC4)=CC=3)N=2)F)=C1 IOLWECNTCVXLQV-UHFFFAOYSA-N 0.000 claims 1
- MVSNVAGWRVEZEP-UHFFFAOYSA-N 5-fluoro-n-[3-methyl-4-(4-methylpiperazin-1-yl)sulfonylphenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C(=C1)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 MVSNVAGWRVEZEP-UHFFFAOYSA-N 0.000 claims 1
- ZWOFTMCYCCXBPH-UHFFFAOYSA-N 5-fluoro-n-[4-(2-methoxyethylsulfonyl)phenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1=CC(S(=O)(=O)CCOC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 ZWOFTMCYCCXBPH-UHFFFAOYSA-N 0.000 claims 1
- TVBCVACLARFLNB-UHFFFAOYSA-N 5-fluoro-n-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-4-[3-(oxan-4-yl)-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(=NC=2)C(F)(F)F)C2CCOCC2)=N1 TVBCVACLARFLNB-UHFFFAOYSA-N 0.000 claims 1
- KWPKLLKLLVEXEJ-UHFFFAOYSA-N 5-fluoro-n-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-4-[3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C=NC=2)C2CCOCC2)=N1 KWPKLLKLLVEXEJ-UHFFFAOYSA-N 0.000 claims 1
- NVAHGLXBXBUJLJ-MRXNPFEDSA-N 5-fluoro-n-[4-[(3r)-3-methylmorpholin-4-yl]sulfonylphenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C[C@@H]1COCCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 NVAHGLXBXBUJLJ-MRXNPFEDSA-N 0.000 claims 1
- ITIVWLXGVTYUJH-PMACEKPBSA-N 5-fluoro-n-[4-[[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]sulfonyl]phenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2S(=O)(=O)C(C=C1)=CC=C1NC(N=1)=NC=C(F)C=1C1=CN=C(C)N1C1CCOCC1 ITIVWLXGVTYUJH-PMACEKPBSA-N 0.000 claims 1
- OQKLTFPVRPDGRN-UHFFFAOYSA-N 6-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-1,1-dioxo-2,3-dihydrothiochromen-4-one;hydrochloride Chemical compound Cl.CC1=NC=C(C=2C(=CN=C(NC=3C=C4C(S(CCC4=O)(=O)=O)=CC=3)N=2)F)N1C1CCOCC1 OQKLTFPVRPDGRN-UHFFFAOYSA-N 0.000 claims 1
- LDARYERYIPQHMP-UHFFFAOYSA-N 6-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-1,1-dioxo-3,4-dihydro-2h-thiochromen-4-ol;hydrochloride Chemical compound Cl.CC1=NC=C(C=2C(=CN=C(NC=3C=C4C(S(CCC4O)(=O)=O)=CC=3)N=2)F)N1C1CCOCC1 LDARYERYIPQHMP-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- VTWOCPCARMHLSC-UHFFFAOYSA-N Cl.NC1=C(C(=O)N(C)CCO)C=CC=C1 Chemical compound Cl.NC1=C(C(=O)N(C)CCO)C=CC=C1 VTWOCPCARMHLSC-UHFFFAOYSA-N 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- VJRZCJVVNSDXRO-UHFFFAOYSA-N [2-chloro-4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 VJRZCJVVNSDXRO-UHFFFAOYSA-N 0.000 claims 1
- NJDCSXXMYGBXEZ-UHFFFAOYSA-N [3-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)=C1 NJDCSXXMYGBXEZ-UHFFFAOYSA-N 0.000 claims 1
- NKXDMFSNIYSZDO-UHFFFAOYSA-N [4-(dimethylamino)piperidin-1-yl]-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 NKXDMFSNIYSZDO-UHFFFAOYSA-N 0.000 claims 1
- ZDHGAOPRJUEXDP-UHFFFAOYSA-N [4-[[4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 ZDHGAOPRJUEXDP-UHFFFAOYSA-N 0.000 claims 1
- BUQKKNYYABDKOK-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-2-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C=1C=C(C(=O)N2CCN(C)CC2)C(OC)=CC=1NC(N=1)=NC=C(F)C=1C1=CN=C(C)N1C1CCOCC1 BUQKKNYYABDKOK-UHFFFAOYSA-N 0.000 claims 1
- NPMJRGJVURWZIN-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-2-methylsulfonylphenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C(=C1)S(C)(=O)=O)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 NPMJRGJVURWZIN-UHFFFAOYSA-N 0.000 claims 1
- TZOGWQIUAPPXRK-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(1,4-oxazepan-4-yl)methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCCOCC1 TZOGWQIUAPPXRK-UHFFFAOYSA-N 0.000 claims 1
- WEPABZWWVXDISQ-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(3-fluoropyrrolidin-1-yl)methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(F)C1 WEPABZWWVXDISQ-UHFFFAOYSA-N 0.000 claims 1
- RSYKUWQLLZMBSK-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(3-hydroxypyrrolidin-1-yl)methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(O)C1 RSYKUWQLLZMBSK-UHFFFAOYSA-N 0.000 claims 1
- DBDXVTYNNKXTKP-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-fluoropiperidin-1-yl)methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(F)CC1 DBDXVTYNNKXTKP-UHFFFAOYSA-N 0.000 claims 1
- MLNSPQGDZLGFAY-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methyl-1,4-diazepan-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 MLNSPQGDZLGFAY-UHFFFAOYSA-N 0.000 claims 1
- WNVLQYNNHQWMHM-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 WNVLQYNNHQWMHM-UHFFFAOYSA-N 0.000 claims 1
- MJCZCHGQXQZPRH-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-propan-2-ylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 MJCZCHGQXQZPRH-UHFFFAOYSA-N 0.000 claims 1
- UBIUTRJXLUTLDV-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-[4-(2-methoxyethyl)piperazin-1-yl]methanone;hydrochloride Chemical compound Cl.C1CN(CCOC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 UBIUTRJXLUTLDV-UHFFFAOYSA-N 0.000 claims 1
- UCEBUYRPLHUGRP-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-piperidin-1-ylmethanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCCCC1 UCEBUYRPLHUGRP-UHFFFAOYSA-N 0.000 claims 1
- LOBZGPAPPRXNJG-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-pyridin-2-ylmethanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)C1=CC=CC=N1 LOBZGPAPPRXNJG-UHFFFAOYSA-N 0.000 claims 1
- UOYZAQZJEFUCIP-UHFFFAOYSA-N [4-[[5-fluoro-4-[3-(oxan-4-yl)-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(=NC=2)C(F)(F)F)C2CCOCC2)=N1 UOYZAQZJEFUCIP-UHFFFAOYSA-N 0.000 claims 1
- MOOUYDFWJLJXCM-UHFFFAOYSA-N [4-[[5-fluoro-4-[3-methyl-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(=NC=2)C(F)(F)F)C)=N1 MOOUYDFWJLJXCM-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- XCPHTBBUCKHUBS-UHFFFAOYSA-N azetidin-1-yl-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC1 XCPHTBBUCKHUBS-UHFFFAOYSA-N 0.000 claims 1
- MLPHHTQRTINTGE-UHFFFAOYSA-N azetidin-1-yl-[4-[[5-fluoro-4-[3-(oxan-4-yl)-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone Chemical compound N1=C(C=2N(C(=NC=2)C(F)(F)F)C2CCOCC2)C(F)=CN=C1NC(C=C1)=CC=C1C(=O)N1CCC1 MLPHHTQRTINTGE-UHFFFAOYSA-N 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000013677 cerebrovascular dementia Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000015654 memory Effects 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- PNJPYAABUAYTTP-UHFFFAOYSA-N n,n-diethyl-4-[[4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(CC)CC)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 PNJPYAABUAYTTP-UHFFFAOYSA-N 0.000 claims 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 1
- FDAWKHKYKBSRPL-UHFFFAOYSA-N n-(4-ethylsulfonylphenyl)-5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 FDAWKHKYKBSRPL-UHFFFAOYSA-N 0.000 claims 1
- XRRKFJUDMHRFHP-UHFFFAOYSA-N n-[3-chloro-4-(4-methylpiperazin-1-yl)sulfonylphenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C(=C1)Cl)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 XRRKFJUDMHRFHP-UHFFFAOYSA-N 0.000 claims 1
- RMZPUORVHIXGKT-UHFFFAOYSA-N n-[3-methyl-4-(4-methylpiperazin-1-yl)sulfonylphenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C(=C1)C)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 RMZPUORVHIXGKT-UHFFFAOYSA-N 0.000 claims 1
- QRKLMCCNSYLNSW-UHFFFAOYSA-N n-[4-(azetidin-1-ylsulfonyl)phenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCC1 QRKLMCCNSYLNSW-UHFFFAOYSA-N 0.000 claims 1
- VMMFFIVOFLAJKC-UHFFFAOYSA-N n-[4-(azetidin-1-ylsulfonyl)phenyl]-5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCC1 VMMFFIVOFLAJKC-UHFFFAOYSA-N 0.000 claims 1
- GGIBZIBINIJURY-UHFFFAOYSA-N n-[4-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]phenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 GGIBZIBINIJURY-UHFFFAOYSA-N 0.000 claims 1
- QVNQBICOSFVRIE-UHFFFAOYSA-N n-[4-[1-(azetidin-1-yl)ethyl]phenyl]-5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C=1C=C(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)C=CC=1C(C)N1CCC1 QVNQBICOSFVRIE-UHFFFAOYSA-N 0.000 claims 1
- LWXJQSQAUIYMFZ-UHFFFAOYSA-N n-[4-[4-(2-methoxyethyl)piperazin-1-yl]sulfonylphenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(CCOC)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 LWXJQSQAUIYMFZ-UHFFFAOYSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- YDVHAJGGRNBAER-UHFFFAOYSA-N pyrimidin-2-amine;hydrochloride Chemical compound Cl.NC1=NC=CC=N1 YDVHAJGGRNBAER-UHFFFAOYSA-N 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0502174 | 2005-10-03 | ||
| PCT/SE2006/001116 WO2007040440A1 (en) | 2005-10-03 | 2006-10-02 | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer’s disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009513575A JP2009513575A (ja) | 2009-04-02 |
| JP2009513575A5 true JP2009513575A5 (enExample) | 2010-11-11 |
Family
ID=37906403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534486A Pending JP2009513575A (ja) | 2005-10-03 | 2006-10-02 | 新規なピリミジン誘導体およびそれらの治療における使用ならびにアルツハイマー病を予防および／または治療するための医薬の製造におけるピリミジン誘導体の使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20090105252A1 (enExample) |
| EP (1) | EP1945628A4 (enExample) |
| JP (1) | JP2009513575A (enExample) |
| KR (1) | KR20080059423A (enExample) |
| CN (1) | CN101326179A (enExample) |
| AR (1) | AR058073A1 (enExample) |
| AU (2) | AU2006297890B2 (enExample) |
| BR (1) | BRPI0616658A2 (enExample) |
| CA (1) | CA2624875A1 (enExample) |
| EC (1) | ECSP088405A (enExample) |
| IL (1) | IL190150A0 (enExample) |
| NO (1) | NO20082067L (enExample) |
| NZ (2) | NZ591316A (enExample) |
| RU (2) | RU2433128C2 (enExample) |
| SG (1) | SG166125A1 (enExample) |
| TW (1) | TW200800957A (enExample) |
| UA (1) | UA92181C2 (enExample) |
| UY (1) | UY29827A1 (enExample) |
| WO (1) | WO2007040440A1 (enExample) |
| ZA (1) | ZA200802897B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (ja) | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体 |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| WO2009017455A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
| WO2010009139A2 (en) * | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| CA2728228A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
| AP3272A (en) | 2008-09-22 | 2015-05-31 | Cayman Chem Co | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases |
| US8178529B2 (en) | 2009-04-15 | 2012-05-15 | Astrazeneca Ab | Imidazole substituted pyrimidines |
| GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
| WO2010144371A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| ES2463826T3 (es) | 2009-06-08 | 2014-05-29 | Gilead Sciences, Inc. | Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina |
| WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| WO2016008966A1 (en) | 2014-07-17 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| JP7671775B2 (ja) * | 2020-03-23 | 2025-05-02 | ファニン ファーマシューティカル カンパニー リミテッド | 新規なピリミジン誘導体及びこれを含む神経退行性疾患及び癌の予防又は治療用組成物 |
| KR102342803B1 (ko) * | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
| TW202227401A (zh) * | 2020-10-23 | 2022-07-16 | 大陸商重慶兩江藥物研發中心有限公司 | 用於持續釋放治療劑的前藥及其用途 |
| KR20230091150A (ko) * | 2020-10-29 | 2023-06-22 | 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 | 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도 |
| JP2024517792A (ja) * | 2021-04-28 | 2024-04-23 | コーネル・ユニバーシティー | 可溶性アデニリルシクラーゼ（ｓＡＣ）阻害剤及びその使用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3530710A1 (de) | 1985-08-28 | 1987-03-05 | Hoechst Ag | Verfahren zur herstellung von halogenphenyl-oxethyl-sulfiden und deren oxidationsprodukten |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| SE0100569D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| ES2316546T3 (es) * | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| BR0213792A (pt) * | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3) |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (ja) * | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体 |
| WO2004005283A1 (en) * | 2002-07-09 | 2004-01-15 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| CA2515132C (en) * | 2003-02-07 | 2012-01-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrroles useful as inhibitors of protein kinases |
| AU2004221881A1 (en) * | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| AU2004261482A1 (en) * | 2003-07-30 | 2005-02-10 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
| TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| US7132651B2 (en) | 2004-04-23 | 2006-11-07 | Framatome Anp, Inc. | In-situ BWR and PWR CRUD flake analysis method and tool |
| CA2617170A1 (en) * | 2005-07-30 | 2007-02-08 | Astrazeneca Ab | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| US8178529B2 (en) * | 2009-04-15 | 2012-05-15 | Astrazeneca Ab | Imidazole substituted pyrimidines |
-
2006
- 2006-09-29 AR ARP060104310A patent/AR058073A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29827A patent/UY29827A1/es not_active Application Discontinuation
- 2006-10-02 JP JP2008534486A patent/JP2009513575A/ja active Pending
- 2006-10-02 WO PCT/SE2006/001116 patent/WO2007040440A1/en not_active Ceased
- 2006-10-02 NZ NZ591316A patent/NZ591316A/en not_active IP Right Cessation
- 2006-10-02 KR KR1020087010755A patent/KR20080059423A/ko not_active Ceased
- 2006-10-02 SG SG201007265-0A patent/SG166125A1/en unknown
- 2006-10-02 RU RU2008110910/04A patent/RU2433128C2/ru not_active IP Right Cessation
- 2006-10-02 CA CA002624875A patent/CA2624875A1/en not_active Abandoned
- 2006-10-02 CN CNA2006800454648A patent/CN101326179A/zh active Pending
- 2006-10-02 NZ NZ566804A patent/NZ566804A/en not_active IP Right Cessation
- 2006-10-02 US US12/089,008 patent/US20090105252A1/en not_active Abandoned
- 2006-10-02 EP EP06799716A patent/EP1945628A4/en not_active Withdrawn
- 2006-10-02 UA UAA200802783A patent/UA92181C2/ru unknown
- 2006-10-02 BR BRPI0616658-0A patent/BRPI0616658A2/pt not_active IP Right Cessation
- 2006-10-02 AU AU2006297890A patent/AU2006297890B2/en not_active Ceased
- 2006-10-03 TW TW095136796A patent/TW200800957A/zh unknown
-
2008
- 2008-03-13 IL IL190150A patent/IL190150A0/en not_active IP Right Cessation
- 2008-04-02 ZA ZA200802897A patent/ZA200802897B/xx unknown
- 2008-04-28 EC EC2008008405A patent/ECSP088405A/es unknown
- 2008-04-30 NO NO20082067A patent/NO20082067L/no not_active Application Discontinuation
-
2011
- 2011-03-03 AU AU2011200948A patent/AU2011200948A1/en not_active Abandoned
- 2011-04-20 RU RU2011115406/04A patent/RU2011115406A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009513575A5 (enExample) | ||
| RU2433128C2 (ru) | Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера | |
| JP2009542638A5 (enExample) | ||
| AU2010286569B2 (en) | Compounds and compositions as protein kinase inhibitors | |
| US8278295B2 (en) | Amino-heterocyclic compounds | |
| RU2401265C2 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| KR101985050B1 (ko) | 피라진카르복사미드 화합물 | |
| CN101370790B (zh) | 作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物 | |
| US9290507B2 (en) | B-RAF kinase inhibitors | |
| RU2008148902A (ru) | Производные имидазол-пиримидина для лечения заболеваний, связанных с киназой гликогенсинтазы 3 (gsk3) | |
| JP2009541268A5 (enExample) | ||
| JP2009542639A5 (enExample) | ||
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| JP2019505595A5 (enExample) | ||
| JP2017530999A5 (enExample) | ||
| AU2018233402A1 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| JP2019523233A5 (enExample) | ||
| JP2005526814A5 (enExample) | ||
| JP2016523911A5 (enExample) | ||
| JP2009525978A5 (enExample) | ||
| RU2016136116A (ru) | Фармацевтические соединения | |
| TW200534853A (en) | Synergistic methods and compositions for treating cancer | |
| RU2009125897A (ru) | Ингибиторы фосфоинозитид-3-киназы и способы их применения | |
| CN101605540A (zh) | 使用mek抑制剂的方法 | |
| JPWO2005063743A1 (ja) | チアゾール誘導体 |